Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future.
|Original language||English (US)|
|Number of pages||9|
|Journal||Journal of neuro-oncology|
|State||Published - Apr 1 2018|
All Science Journal Classification (ASJC) codes
- Clinical Neurology
- Cancer Research